<DOC>
	<DOCNO>NCT00633269</DOCNO>
	<brief_summary>Open , non-randomized , radiolabelled , single centre study design characterize metabolism , excretion pharmacokinetics single oral dose 100 mg [ 14C ] -radiolabelled AZD2281 ( KU-0059436 ) patient advance metastatic solid tumour .</brief_summary>
	<brief_title>Study Assessing Metabolism , Excretion Pharmacokinetics Poly ( ADP-Ribose ) Polymerase ( PARP ) Inhibitor Patients With Solid Metastatic Tumours</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<criteria>Histologically confirm advanced metastatic tumour , refractory standard therapy Anticancer therapy include chemotherapy , radiotherapy ( exclude palliative radiotherapy ) , endocrine therapy , immunotherapy use investigational agent within 4 week prior study entry . Patients may continue use LHRH agonist cancer , bisphosphonates bone disease corticosteroid provide dose stable study . Females able continue take hormone replacement therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Poly ( ADP ribose ) polymerase</keyword>
	<keyword>Metastatic Solid Tumours</keyword>
</DOC>